S

Sandoz Group AG
SIX:SDZ

Watchlist Manager
Sandoz Group AG
SIX:SDZ
Watchlist
Price: 37.06 CHF -0.22% Market Closed
Market Cap: 16.3B CHF
Have any thoughts about
Sandoz Group AG?
Write Note

Relative Value

The Relative Value of one SDZ stock under the Base Case scenario is 48.47 CHF. Compared to the current market price of 37.06 CHF, Sandoz Group AG is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SDZ Relative Value
Base Case
48.47 CHF
Undervaluation 24%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
58
Median 3Y
1.5
Median 5Y
1.5
Industry
2.5
Forward
1.7
vs History
31
vs Industry
1
Median 3Y
197.4
Median 5Y
197.4
Industry
21.8
Forward
14.5
vs History
31
vs Industry
9
Median 3Y
42
Median 5Y
42
Industry
16.1
vs History
43
vs Industry
34
Median 3Y
4.7
Median 5Y
4.7
Industry
23.8
vs History
31
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.1
vs History
31
vs Industry
57
Median 3Y
1.5
Median 5Y
1.5
Industry
2.7
Forward
2
vs History
31
vs Industry
53
Median 3Y
3.3
Median 5Y
3.3
Industry
5.2
vs History
31
vs Industry
35
Median 3Y
8.5
Median 5Y
8.5
Industry
13.5
Forward
10.1
vs History
31
vs Industry
32
Median 3Y
12.1
Median 5Y
12.1
Industry
16.8
Forward
12.1
vs History
31
vs Industry
9
Median 3Y
42.2
Median 5Y
42.2
Industry
15.2
vs History
vs Industry
Median 3Y
-58
Median 5Y
-58
Industry
19.3
vs History
31
vs Industry
Median 3Y
0
Median 5Y
0
Industry
1.9

Multiples Across Competitors

SDZ Competitors Multiples
Sandoz Group AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Sandoz Group AG
SIX:SDZ
15.9B CHF 1.8 229.8 11.8 16.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
CH
S
Sandoz Group AG
SIX:SDZ
Average P/S: 382 942.1
1.8
20%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
CH
S
Sandoz Group AG
SIX:SDZ
Average P/E: 54.4
229.8
2 110%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
S
Sandoz Group AG
SIX:SDZ
Average EV/EBITDA: 414.8
11.8
53%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
S
Sandoz Group AG
SIX:SDZ
Average EV/EBIT: 1 811.8
16.7
87%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top